News

CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

The biomarkers are especially crucial for patients with lupus nephritis

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

Discover how dropless cataract surgery enhances patient comfort and outcomes, reducing the need for eye drops and improving recovery efficiency.

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs)

At Retina World Congress 2025, Dilsher S. Dhoot, MD, shares updates on the HELIOS trial and the potential future of tyrosine kinase inhibitors (TKIs).

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential impacts on vision and ocular health.

This large database study explored the link between autoimmune problems and AMD.

In this conversation, Franklin discussed a research study on intraoperative fluorescein angiography in surgical procedures, highlighting significant advancements in surgical visualization and patient outcomes.

Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

The LuxLife full range of vision intraocular lens is available in a range of cylinders spanning from +0.75D to +6.00D.

Teprotumumab is the first therapy specifically licensed for the treatment of moderate-to-severe thyroid eye disease in the UK

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Galimedix Therapeutics advances GAL-101, an oral therapy targeting Alzheimer’s and AMD, completing phase 1 SAD study with promising safety results.

Exploring how oral sedation and office-based surgery can enhance efficiency and patient experience